On the ethics of pharmaceutical protein production in transgenic animals

Public Deposited

Citeable URL: https://ir.library.oregonstate.edu/concern/defaults/3j333643g

Descriptions

Attribute Name	Values
Creator	Mangan, Emily
Abstract	Humans have been practicing various forms of biotechnology since early domestication, 7,000-10,000 years ago (Macnaghten, 2004). Biotechnology is an umbrella term for many scientific applications to biology, the oldest being selective breeding (Macnaghten, 2004). In the last few decades, however, the field of biotechnology has gravitated towards genetic engineering, gene splicing, and transgenics as fields of scientific pursuit (Frewer, 2013; Wei, 1997; Verhoog, 1996). An emerging technology is the use of transgenic animals to produce pharmaceutical proteins (Wei, 1997; Macnaghten, 2004). This is a complex ethical issue that involves many stakeholders, including the pharmaceutical company, the consumer, and the animals used. This paper will discuss the ethics of pharmaceutical protein production in transgenic animals in relation to perceived welfare, actual welfare, and by evaluation by application of three ethical philosophies: utilitarian, rights-based, and deontological.
License	Attribution-NonCommercial-NoDerivs 3.0 United States
Resource Type	Research Paper
Date Available	2014-06-02T23:02:14+00:00
Date Issued	2014-03-05
Degree Level	Bachelor's
Non-Academic Affiliation	Oregon State University. Writing Intensive Curriculum
Rights Statement	In Copyright
Publisher	Oregon State University
Peer Reviewed	No
Language	English [eng]
Replaces	http://hdl.handle.net/1957/48711

Parents:

This work has no parents.

In Collection:

Thumbnail	Title	Date Uploaded	Visibility	Actions
	On_Ethics_Pharmaceutical_Protein_Mangan.pdf	2017-09-26	Public	Download